Opthea Presents Phase 1/2a Data of OPT-302 in wet AMD at the Retina Society 2018 Annual Meeting

World News: . []

MELBOURNE Australia Sept 14 2018 GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage clinical biopharmaceutical company developing first-in-class novel biologic therapies to treat back-of-the-eye diseases announced today that new clini cal dat...

More news and information about Opthea Limited

Published By:

Globe Newswire: 10:30 GMT Friday 14th September 2018

Published: .

Search for other references to "opthea" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us